

Robert Yarchoan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3859470/publications.pdf>

Version: 2024-02-01

72
papers

7,198
citations

87401

40
h-index

100535

70
g-index

74
all docs

74
docs citations

74
times ranked

6223
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncologic Treatment of HIV-Associated Kaposi Sarcoma 40 Years on. <i>Journal of Clinical Oncology</i> , 2022, 40, 294-306.	0.8	17
2	Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy. <i>Science Translational Medicine</i> , 2022, 14, eabl3836.	5.8	50
3	Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection. <i>Clinical Cancer Research</i> , 2022, 28, 840-850.	3.2	20
4	Transient Viral Activation in Human T Cell Leukemia Virus Type 1-Infected Macaques Treated With Pomalidomide. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	4
5	CDK4/6 inhibitors sensitize gammaherpesvirus-infected tumor cells to T-cell killing by enhancing expression of immune surface molecules. <i>Journal of Translational Medicine</i> , 2022, 20, 217.	1.8	9
6	Immunotherapy for KSHV-associated diseases. <i>Current Opinion in Virology</i> , 2022, 55, 101249.	2.6	4
7	A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication. <i>Nature Communications</i> , 2021, 12, 668.	5.8	126
8	Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma. , 2021, 9, e002097.		28
9	Characteristics and outcomes of KSHV-associated multicentric Castlemans disease with or without other KSHV diseases. <i>Blood Advances</i> , 2021, 5, 1660-1670.	2.5	35
10	Regulation of the Dimerization and Activity of SARS-CoV-2 Main Protease through Reversible Glutathionylation of Cysteine 300. <i>MBio</i> , 2021, 12, e0209421.	1.8	13
11	Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2. <i>PLoS Pathogens</i> , 2021, 17, e1009091.	2.1	16
12	Analysis of Ugandan cervical carcinomas identifies human papillomavirus clade-specific epigenome and transcriptome landscapes. <i>Nature Genetics</i> , 2020, 52, 800-810.	9.4	40
13	GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection. <i>MBio</i> , 2020, 11, .	1.8	52
14	Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer. <i>Current HIV/AIDS Reports</i> , 2020, 17, 547-556.	1.1	21
15	Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castlemans disease. <i>Blood</i> , 2020, 135, 2316-2319.	0.6	33
16	Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate. <i>Blood</i> , 2020, 136, 2229-2232.	0.6	26
17	Induction of Kaposi's Sarcoma-Associated Herpesvirus-Encoded Thymidine Kinase (ORF21) by X-Box Binding Protein 1. <i>Journal of Virology</i> , 2020, 94, .	1.5	6
18	A phase I trial of pomalidomide in combination with liposomal doxorubicin in patients with Kaposi sarcoma with or without other KSHV-associated diseases.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11552-11552.	0.8	3

#	ARTICLE	IF	CITATIONS
19	No evidence of ongoing HIV replication or compartmentalization in tissues during combination antiretroviral therapy: Implications for HIV eradication. <i>Science Advances</i> , 2019, 5, eaav2045.	4.7	60
20	Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells. <i>Oncolimmunology</i> , 2019, 8, e1546544.	2.1	23
21	Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study. <i>JAMA Oncology</i> , 2019, 5, 1332.	3.4	153
22	A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma. <i>Clinical Cancer Research</i> , 2019, 25, 4238-4247.	3.2	17
23	Viral, immunologic, and clinical features of primary effusion lymphoma. <i>Blood</i> , 2019, 133, 1753-1761.	0.6	87
24	HIV-Associated Cancers and Related Diseases. <i>New England Journal of Medicine</i> , 2018, 378, 1029-1041.	13.9	327
25	Metagenomic Discovery of 83 New Human Papillomavirus Types in Patients with Immunodeficiency. <i>MSphere</i> , 2018, 3, .	1.3	75
26	HIV-Associated Cancers and Related Diseases. <i>New England Journal of Medicine</i> , 2018, 378, 2144-2145.	13.9	33
27	Identification of functional hypoxia inducible factor response elements in the human lysyl oxidase gene promoter. <i>Biochemical and Biophysical Research Communications</i> , 2017, 490, 480-485.	1.0	33
28	Kaposi sarcoma herpesvirus-associated cancers and related diseases. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 47-56.	1.5	120
29	HIV-associated Kaposi sarcoma and related diseases. <i>Aids</i> , 2017, 31, 1903-1916.	1.0	97
30	A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented nM to pM potency. <i>ELife</i> , 2017, 6, .	2.8	44
31	RNA Sequencing Reveals that Kaposi Sarcoma-Associated Herpesvirus Infection Mimics Hypoxia Gene Expression Signature. <i>PLoS Pathogens</i> , 2017, 13, e1006143.	2.1	28
32	T-cell responses to KSHV infection: a systematic approach. <i>Oncotarget</i> , 2017, 8, 109402-109416.	0.8	29
33	Hypoxia-inducible factor-1 alpha as a therapeutic target for primary effusion lymphoma. <i>PLoS Pathogens</i> , 2017, 13, e1006628.	2.1	30
34	Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide. <i>Oncotarget</i> , 2017, 8, 50342-50358.	0.8	28
35	Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 4125-4131.	0.8	91
36	Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS). <i>Clinical Infectious Diseases</i> , 2016, 62, 730-738.	2.9	135

#	ARTICLE	IF	CITATIONS
37	Induction of Kaposi's Sarcoma-Associated Herpesvirus-Encoded Viral Interleukin-6 by X-Box Binding Protein 1. <i>Journal of Virology</i> , 2016, 90, 368-378.	1.5	26
38	Next-Generation Sequencing Analysis Reveals Differential Expression Profiles of miRNA-mRNA Target Pairs in KSHV-Infected Cells. <i>PLoS ONE</i> , 2015, 10, e0126439.	1.1	19
39	Kaposi Sarcoma-Associated Herpesvirus-Associated Malignancies: Epidemiology, Pathogenesis, and Advances in Treatment. <i>Seminars in Oncology</i> , 2015, 42, 223-246.	0.8	122
40	Inflammatory Cytokines, Hyperferritinemia and IgE Are Prognostic in Patients with KSHV-Associated Lymphomas Treated with Curative Intent Therapy. <i>Blood</i> , 2014, 124, 3001-3001.	0.6	3
41	Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castlemans disease. <i>Blood</i> , 2013, 122, 4189-4198.	0.6	141
42	Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Induction by Hypoxia and Hypoxia-Inducible Factors. <i>Journal of Virology</i> , 2012, 86, 1097-1108.	1.5	34
43	Phase II Study of Bevacizumab in Patients With HIV-Associated Kaposi's Sarcoma Receiving Antiretroviral Therapy. <i>Journal of Clinical Oncology</i> , 2012, 30, 1476-1483.	0.8	103
44	Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castlemans Disease (KSHV-associated MCD) and the KSHV Inflammatory Cytokine Syndrome. <i>Frontiers in Microbiology</i> , 2012, 3, 73.	1.5	150
45	High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castlemans disease: a pilot study of virus-activated cytotoxic therapy. <i>Blood</i> , 2011, 117, 6977-6986.	0.6	149
46	Kaposi's sarcoma-associated herpesviral IL-6 and human IL-6 open reading frames contain miRNA binding sites and are subject to cellular miRNA regulation. <i>Journal of Pathology</i> , 2011, 225, 378-389.	2.1	59
47	Cancer Burden in the HIV-Infected Population in the United States. <i>Journal of the National Cancer Institute</i> , 2011, 103, 753-762.	3.0	698
48	Characterization of the Activation of Protein Tyrosine Phosphatase, Receptor-Type, Z Polypeptide 1 (PTPRZ1) by Hypoxia Inducible Factor-2 Alpha. <i>PLoS ONE</i> , 2010, 5, e9641.	1.1	27
49	An Interleukin-6-Related Systemic Inflammatory Syndrome in Patients Co-infected with Kaposi Sarcoma-Associated Herpesvirus and HIV but without Multicentric Castlemans Disease. <i>Clinical Infectious Diseases</i> , 2010, 51, 350-358.	2.9	266
50	Hypoxia Enhances the Phosphorylation and Cytotoxicity of Ganciclovir and Zidovudine in Kaposi's Sarcoma-Associated Herpesvirus-Infected Cells. <i>Cancer Research</i> , 2007, 67, 7003-7010.	0.4	44
51	Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma. <i>Blood</i> , 2007, 110, 4165-4171.	0.6	51
52	Genetic Organization and Hypoxic Activation of the Kaposi's Sarcoma-Associated Herpesvirus ORF34-37 Gene Cluster. <i>Journal of Virology</i> , 2006, 80, 7037-7051.	1.5	59
53	Differential Gene Up-Regulation by Hypoxia-Inducible Factor-1 and Hypoxia-Inducible Factor-2 in HEK293T Cells. <i>Cancer Research</i> , 2005, 65, 3299-3306.	0.4	282
54	Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Contains Hypoxia Response Elements: Relevance to Lytic Induction by Hypoxia. <i>Journal of Virology</i> , 2003, 77, 6761-6768.	1.5	107

#	ARTICLE	IF	CITATIONS
55	Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. <i>Blood</i> , 2001, 97, 3244-3250.	0.6	220
56	Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders. <i>Blood</i> , 2001, 97, 2173-2176.	0.6	114
57	Transcription Program of Human Herpesvirus 8 (Kaposi's Sarcoma-Associated Herpesvirus). <i>Journal of Virology</i> , 2001, 75, 4843-4853.	1.5	198
58	Activity of Thalidomide in AIDS-Related Kaposi's Sarcoma. <i>Journal of Clinical Oncology</i> , 2000, 18, 2593-2602.	0.8	288
59	Involvement of Interleukin-10 (IL-10) and Viral IL-6 in the Spontaneous Growth of Kaposi's Sarcoma Herpesvirus-Associated Infected Primary Effusion Lymphoma Cells. <i>Blood</i> , 1999, 94, 2871-2879.	0.6	228
60	Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells. <i>Blood</i> , 1999, 94, 2871-9.	0.6	114
61	Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma.. <i>Journal of Clinical Oncology</i> , 1998, 16, 1112-1121.	0.8	162
62	Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications. <i>Clinical Pharmacology and Therapeutics</i> , 1991, 50, 278-285.	2.3	63
63	Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future. <i>Blood</i> , 1991, 78, 859-84.	0.6	24
64	Pharmacokinetics of 2â€², 3â€²-dideoxyadenosine and 2â€², 3â€²-dideoxyinosine in patients with severe human immunodeficiency virus infection. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 47, 647-654.	2.3	148
65	Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection [see comments]. <i>Blood</i> , 1990, 76, 463-472.	0.6	101
66	Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex. <i>Lancet</i> , The, 1990, 336, 526-529.	6.3	233
67	Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection [see comments]. <i>Blood</i> , 1990, 76, 463-472.	0.6	0
68	Strategies for the combination therapy of HIV infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1990, 3 Suppl 2, S99-103.	1.0	1
69	In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. <i>Science</i> , 1989, 245, 412-415.	6.0	424
70	Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2',3'-dideoxycytidine (ddc). <i>Muscle and Nerve</i> , 1989, 12, 856-860.	1.0	110
71	Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 46, 494-499.	2.3	120
72	Plasma and cerebrospinal fluid pharmacokinetics of 3â€²-azido-3â€²-deoxythymidine: A Novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. <i>Clinical Pharmacology and Therapeutics</i> , 1987, 41, 407-412.	2.3	396